{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T21:24:09Z","timestamp":1784064249509,"version":"3.55.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100003161","name":"National Alopecia Areata Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003161","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R13AR074890"],"award-info":[{"award-number":["R13AR074890"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003161","name":"National Alopecia Areata Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003161","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003161","name":"National Alopecia Areata Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003161","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidsponline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology Symposium Proceedings"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.jisp.2020.04.004","type":"journal-article","created":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T05:10:13Z","timestamp":1603257013000},"page":"S28-S30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Current Treatment of Alopecia Areata"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7790-3895","authenticated-orcid":false,"given":"Maria K.","family":"Hordinsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jisp.2020.04.004_bib1","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1001\/jamadermatol.2014.504","article-title":"Effects of low-dose recombinant interleukin 2 to promote T- regulatory cells in alopecia areata","volume":"150","author":"Castela","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jisp.2020.04.004_bib2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2016.09.006","article-title":"Tofacitinib for the treatment of alopecia areata and variants in adolescents","volume":"76","author":"Craiglow","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jisp.2020.04.004_bib3","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jamadermatol.2015.4445","article-title":"Topical ruxolitinib for the treatment of alopecia universalis","volume":"152","author":"Craiglow","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jisp.2020.04.004_bib4","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40257-014-0086-4","article-title":"Alopecia areata: an evidence-based treatment update","volume":"15","author":"Hordinsky","year":"2014","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jisp.2020.04.004_bib5","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1038\/jidsymp.2013.4","article-title":"Overview of alopecia areata","volume":"16","author":"Hordinsky","year":"2013","journal-title":"J\u00a0Investig Dermatol Symp Proc"},{"key":"10.1016\/j.jisp.2020.04.004_bib6","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/exd.13060","article-title":"Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers","volume":"25","author":"Jabbari","year":"2016","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jisp.2020.04.004_bib7","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jaad.2014.11.006","article-title":"Treatment of alopecia areata with simvastatin\/ezetimibe","volume":"72","author":"Lattouf","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jisp.2020.04.004_bib8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jamadermatol.2013.5764","article-title":"Clobetasol propionate, 0.05%, vs hydrocortisone, 1%, for alopecia areata in children: a randomized clinical trial","volume":"150","author":"Lenane","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jisp.2020.04.004_bib9","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.jaad.2018.02.018","article-title":"Rethinking biotin therapy for hair, nail, and skin disorders","volume":"78","author":"Lipner","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jisp.2020.04.004_bib10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","article-title":"Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients","volume":"76","author":"Liu","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jisp.2020.04.004_bib11","doi-asserted-by":"crossref","first-page":"e89790","DOI":"10.1172\/jci.insight.89790","article-title":"Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata","volume":"1","author":"Mackay-Wiggan","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.jisp.2020.04.004_bib12","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jaad.2017.10.048","article-title":"Objective outcome measures: collecting meaningful data on alopecia areata","volume":"79","author":"Olsen","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jisp.2020.04.004_bib13","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jaad.2008.08.029","article-title":"Lack of efficacy of topical latanoporst and bimatoprost ophthalmic solutions in promoting eyelash growth in patients with alopecia areata","volume":"60","author":"Roseborough","year":"2009","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jisp.2020.04.004_bib14","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjd.12397","article-title":"A\u00a0randomized, double\u2013blind, placebo-and active-controlled, half-head study to evaluate the effects of platelet-rich plasma on alopecia areata","volume":"169","author":"Trink","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jisp.2020.04.004_bib15","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/j.jaad.2018.07.055","article-title":"Response to: \u201cRethinking biotin therapy for hair, nail, and skin disorders\u201d","volume":"79","author":"Walth","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"}],"container-title":["Journal of Investigative Dermatology Symposium Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1087002420300046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1087002420300046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:21:02Z","timestamp":1761067262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1087002420300046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1087002420300046"],"URL":"https:\/\/doi.org\/10.1016\/j.jisp.2020.04.004","relation":{},"ISSN":["1087-0024"],"issn-type":[{"value":"1087-0024","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current Treatment of Alopecia Areata","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology Symposium Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jisp.2020.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}